Status:
COMPLETED
Imunomodulation in Acute Pancreatitis
Lead Sponsor:
Filipa Malheiro
Conditions:
Acute Pancreatitis
Eligibility:
All Genders
18-85 years
Brief Summary
Acute pancreatitis is an acute inflammatory pathology of the pancreas with activation of both innate and adaptive immune system, including T and B lymphocytes and release of inflammatory cytokines. We...
Eligibility Criteria
Inclusion
- hospitalized patients with acute pancreatitis
Exclusion
- acute pancreatitis in the last 6 months diabetes mellitus, pregnant women, uncontrolled comorbidity such as organ disease (cardiac, renal, hepatic) and terminal neoplasms
Key Trial Info
Start Date :
February 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04796311
Start Date
February 26 2021
End Date
December 30 2023
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital da Luz
Lisbon, Portugal